Literature DB >> 17429432

Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels.

N Widmer, H Rumpold, G Untergasser, A Fayet, T Buclin, L A Decosterd.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17429432     DOI： 10.1038/sj.leu.2404671

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

Review 1.  Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?

Authors:  Margaret von Mehren; Nicolas Widmer
Journal:  Cancer Treat Rev       Date:  2010-11-24       Impact factor: 12.111

Review 2.  Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

Authors:  Chung-Pu Wu; Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Curr Mol Pharmacol       Date:  2008-06       Impact factor: 3.339

Review 3.  ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.

Authors:  Jiexin Deng; Jie Shao; John S Markowitz; Guohua An
Journal:  Pharm Res       Date:  2014-05-20       Impact factor: 4.200

Review 4.  Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.

Authors:  Suneet Shukla; Zhe-Sheng Chen; Suresh V Ambudkar
Journal:  Drug Resist Updat       Date:  2012-02-09       Impact factor: 18.500

5.  Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.

Authors:  Athina Giannoudis; Andrea Davies; Claire M Lucas; Robert J Harris; Munir Pirmohamed; Richard E Clark
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

6.  The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy.

Authors:  Olga A Patutina; Nadezda L Mironova; Nelly A Popova; Vasily I Kaledin; Valery P Nikolin; Valentin V Vlassov; Marina A Zenkova
Journal:  BMC Cancer       Date:  2010-05-14       Impact factor: 4.430

7.  Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

Authors:  J Rafael Sierra; Virna Cepero; Silvia Giordano
Journal:  Mol Cancer       Date:  2010-04-12       Impact factor: 27.401

8.  Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.

Authors:  Wenyong W Zhang; Jorge E Cortes; Hui Yao; Li Zhang; Neelima G Reddy; Elias Jabbour; Hagop M Kantarjian; Dan Jones
Journal:  J Clin Oncol       Date:  2009-06-08       Impact factor: 44.544

9.  Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.

Authors:  Suneet Shukla; Robert W Robey; Susan E Bates; Suresh V Ambudkar
Journal:  Drug Metab Dispos       Date:  2008-10-29       Impact factor: 3.922

Review 10.  Improving cancer chemotherapy with modulators of ABC drug transporters.

Authors:  S Shukla; S Ohnuma; S V Ambudkar
Journal:  Curr Drug Targets       Date:  2011-05       Impact factor: 3.465
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.